title: Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
authors.affiliation: Department of Cutaneous Allergy, St John's Institute of Dermatology, Guy's & St. Thomas' Hospitals, London SE1 9RT, UK.
authors.forename: Hannah
authors.initials: H
authors.lastname: Cookson
authors.affiliation: Department of Cutaneous Allergy, St John's Institute of Dermatology, Guy's & St. Thomas' Hospitals, London SE1 9RT, UK.
authors.forename: John
authors.initials: J
authors.lastname: McFadden
authors.affiliation: Department of Cutaneous Allergy, St John's Institute of Dermatology, Guy's & St. Thomas' Hospitals, London SE1 9RT, UK.
authors.forename: Jonathan
authors.initials: J
authors.lastname: White
authors.affiliation: Department of Cutaneous Allergy, St John's Institute of Dermatology, Guy's & St. Thomas' Hospitals, London SE1 9RT, UK.
authors.forename: Ian R
authors.initials: IR
authors.lastname: White
mesh_terms: D000279:Administration, Cutaneous; D058647:Adrenergic alpha-2 Receptor Agonists / Q000009:adverse effects*; D000068438:Brimonidine Tartrate / Q000009:adverse effects*; D017449:Dermatitis, Allergic Contact / Q000209:etiology*; D003879:Dermatologic Agents / Q000009:adverse effects*; D005148:Facial Dermatoses / Q000139:chemically induced*; D005260:Female; D005782:Gels; D006801:Humans; D012393:Rosacea / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D003879:Dermatologic Agents; D005782:Gels; D000068438:Brimonidine Tartrate
keywords: brimonidine tartrate; contact allergy